Zoetis Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Kristin C. Peck
- Full Time Employees
- 14,500
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 10 Sylvan Way Parsippany NJ United States 07054
- IPO Date
- Feb 1, 2013
- CIK
- 0001555280
- Website
- zoetis.com
- Similar Companies
- Business
- Zoetis Inc. (NYSE: ZTS) develops, manufactures and commercializes animal health medicines and vaccines, as well as a range of other animal health products and services. The company offers pharmaceuticals including anti-infectives, dermatology products, pain and sedation therapeutics, and reproductive controls; vaccines for livestock and companion animals such as dogs, cats, horses and cattle; and diagnostics, parasiticides, dermatology treatments, medicated topicals, vaccines and therapeutics for small and large animals. Zoetis provides platform technologies like the Zoetis Petcare solutions for pet owners and veterinarians, including telehealth services and data-driven insights, along with contract manufacturing and research services for biopharmaceuticals. Operating in over 100 countries with a primary focus on North America, Europe, and emerging markets in Latin America, Asia and Africa, the company targets veterinarians, livestock producers and pet owners as key customers. Founded in 2012 as a spin-off from Pfizer Inc.'s animal health business and headquartered in Parsippany, New Jersey, Zoetis has no major parent company or significant subsidiaries beyond its global operating units. In recent developments, Zoetis expanded its portfolio through the 2024 launch of new monoclonal antibody therapies for canine osteoarthritis and atopic dermatitis under the Libertym brand, formed a strategic alliance with Pharmgate Animal Health in 2025 for U.S. swine feed antibiotics distribution, and completed the acquisition of Basepaws in 2023 to bolster its pet genetics and diagnostics capabilities, reflecting ongoing innovation and market penetration efforts.
Company News
Zoetis (ZTS) Ascends While Market Falls: Some Facts to Note
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
3 Absurdly Cheap Dividend Stocks to Buy for Under $100 Right Now
Which Pharmaceutical ETF Is the Better Buy: iShares’ Domestic IHE or VanEck’s Global PPH?
Zoetis (ZTS) Registers a Bigger Fall Than the Market: Important Facts to Note
ZTS vs. ICCC: Which Animal Health Stock Is the Better Investment Bet?
Zoetis Receives FDA Approval for Convenia® RTU for Dogs (cefovecin injectable suspension), Helping More Medium and Large Dogs Access Single-Injection Treatment
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Akamai Technolgies, Apple, Blackrock, Ford Motor, Healthcare Realty Trust, Noble, Sunoco LP, Venture Global, Western Midstream Partners, Zoetis, and More
8,293 Zoetis Inc. $ZTS Shares Sold by Banque Pictet & Cie SA
Zoetis Appoints Iris Knobloch to its Board of Directors
10 Dividend Growth Stocks: October 2026
Top 50 High-Quality Dividend Growth Stocks For October 2026
Zoetis (ZTS) Outpaces Stock Market Gains: What You Should Know
A Once-in-a-Decade Opportunity: 2 Magnificent Dividend Stocks Down 34% to 52% I'm Buying Right Now
Zoetis Declares Fourth Quarter 2026 Dividend
New Peer-Reviewed Publication on Laboratory Study That Demonstrated Simparica Trio® Protected 3x More Dogs From Infection With a Resistant Heartworm Isolate Than NexGard® Plus1
40,294 Zoetis Inc. $ZTS Shares Purchased by Rockland Trust Co.
Zoetis (ZTS) Stock Sinks As Market Gains: Here's Why
Zoetis: Priced For The Worst, Worth Buying
Zoetis (ZTS) Registers a Bigger Fall Than the Market: Important Facts to Note